132 related articles for article (PubMed ID: 8626396)
21. Heparin binding domain of insulin-like growth factor binding protein-5 stimulates mesangial cell migration.
Abrass CK; Berfield AK; Andress DL
Am J Physiol; 1997 Dec; 273(6):F899-906. PubMed ID: 9435678
[TBL] [Abstract][Full Text] [Related]
22. Insulin-like growth factor-binding protein 5 complexes with the acid-labile subunit. Role of the carboxyl-terminal domain.
Twigg SM; Kiefer MC; Zapf J; Baxter RC
J Biol Chem; 1998 Oct; 273(44):28791-8. PubMed ID: 9786878
[TBL] [Abstract][Full Text] [Related]
23. Glycosylation of insulin-like growth factor binding protein-3 (IGFBP-3) is not required for potentiation of IGF-I action: evidence for processing of cell-bound IGFBP-3.
Conover CA
Endocrinology; 1991 Dec; 129(6):3259-68. PubMed ID: 1720092
[TBL] [Abstract][Full Text] [Related]
24. Role of insulin-like growth factor binding proteins in the control of IGF actions.
Clemmons DR; Busby WH; Arai T; Nam TJ; Clarke JB; Jones JI; Ankrapp DK
Prog Growth Factor Res; 1995; 6(2-4):357-66. PubMed ID: 8817679
[TBL] [Abstract][Full Text] [Related]
25. Factors regulating insulin-like growth factor-binding protein-3 binding, processing, and potentiation of insulin-like growth factor action.
Conover CA; Clarkson JT; Bale LK
Endocrinology; 1996 Jun; 137(6):2286-92. PubMed ID: 8641177
[TBL] [Abstract][Full Text] [Related]
26. Regulation of vascular smooth muscle cell responses to insulin-like growth factor (IGF)-I by local IGF-binding proteins.
Hsieh T; Gordon RE; Clemmons DR; Busby WH; Duan C
J Biol Chem; 2003 Oct; 278(44):42886-92. PubMed ID: 12917428
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs.
Oh Y; Müller HL; Lee DY; Fielder PJ; Rosenfeld RG
Endocrinology; 1993 Mar; 132(3):1337-44. PubMed ID: 7679979
[TBL] [Abstract][Full Text] [Related]
28. Solid-phase assay for insulin-like growth factor (IGF) binding to IGF-binding protein-3: application to the study of the effects of antibodies and heparin.
Koedam JA; Hoogerbrugge CM; van Buul-Offers SC; Van den Brande JL
J Endocrinol; 1997 Apr; 153(1):87-97. PubMed ID: 9135573
[TBL] [Abstract][Full Text] [Related]
29. Insulin-like growth factor binding protein-5 (IGFBP-5) interacts with thrombospondin-1 to induce negative regulatory effects on IGF-I actions.
Moralez AM; Maile LA; Clarke J; Busby WH; Clemmons DR
J Cell Physiol; 2005 May; 203(2):328-34. PubMed ID: 15700281
[TBL] [Abstract][Full Text] [Related]
30. Recombinant human insulin-like growth factor binding proteins 4, 5, and 6: biological and physiochemical characterization.
Kiefer MC; Schmid C; Waldvogel M; Schläpfer I; Futo E; Masiarz FR; Green K; Barr PJ; Zapf J
Growth Regul; 1993 Mar; 3(1):56-9. PubMed ID: 7683532
[TBL] [Abstract][Full Text] [Related]
31. Glycosaminoglycan binding characteristics of the insulin-like growth factor-binding proteins.
Hodgkinson SC; Napier JR; Spencer GS; Bass JJ
J Mol Endocrinol; 1994 Aug; 13(1):105-12. PubMed ID: 7528019
[TBL] [Abstract][Full Text] [Related]
32. Multivalent cations depress ligand binding to cell-associated insulin-like growth factor binding protein-5 on human glioblastoma cells.
Sackett RL; McCusker RH
Endocrinology; 1998 Apr; 139(4):1943-51. PubMed ID: 9528981
[TBL] [Abstract][Full Text] [Related]
33. Discovery and characterization of IGFBP-mediated endocytosis in the human retinal pigment epithelial cell line ARPE-19.
Ainscough SL; Feigl B; Malda J; Harkin DG
Exp Eye Res; 2009 Nov; 89(5):629-37. PubMed ID: 19540231
[TBL] [Abstract][Full Text] [Related]
34. Mutagenesis of basic amino acids in the carboxyl-terminal region of insulin-like growth factor binding protein-5 affects acid-labile subunit binding.
Firth SM; Clemmons DR; Baxter RC
Endocrinology; 2001 May; 142(5):2147. PubMed ID: 11316783
[TBL] [Abstract][Full Text] [Related]
35. A central domain binding site in insulin-like growth factor binding protein-5 for the acid-labile subunit.
Twigg SM; Kiefer MC; Zapf J; Baxter RC
Endocrinology; 2000 Jan; 141(1):454-7. PubMed ID: 10614670
[TBL] [Abstract][Full Text] [Related]
36. Plasmin degradation of insulin-like growth factor-binding protein-5 (IGFBP-5): regulation by IGFBP-5-(201-218).
Campbell PG; Andress DL
Am J Physiol; 1997 Nov; 273(5):E996-1004. PubMed ID: 9374687
[TBL] [Abstract][Full Text] [Related]
37. Fibronectin binds insulin-like growth factor-binding protein 5 and abolishes Its ligand-dependent action on cell migration.
Xu Q; Yan B; Li S; Duan C
J Biol Chem; 2004 Feb; 279(6):4269-77. PubMed ID: 14645245
[TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) functions as an IGF-reversible inhibitor of IGFBP-4 proteolysis.
Fowlkes JL; Serra DM; Rosenberg CK; Thrailkill KM
J Biol Chem; 1995 Nov; 270(46):27481-8. PubMed ID: 7499205
[TBL] [Abstract][Full Text] [Related]
39. Interaction of insulin-like growth factor II (IGF-II) with multiple plasma proteins: high affinity binding of plasminogen to IGF-II and IGF-binding protein-3.
Oesterreicher S; Blum WF; Schmidt B; Braulke T; Kübler B
J Biol Chem; 2005 Mar; 280(11):9994-10000. PubMed ID: 15642732
[TBL] [Abstract][Full Text] [Related]
40. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions.
Kalus W; Zweckstetter M; Renner C; Sanchez Y; Georgescu J; Grol M; Demuth D; Schumacher R; Dony C; Lang K; Holak TA
EMBO J; 1998 Nov; 17(22):6558-72. PubMed ID: 9822601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
